Company Filing History:
Years Active: 2016-2021
Title: Corwin Nycholat: Innovator in Allergy Treatment and Immune Modulation
Introduction
Corwin Nycholat is a prominent inventor based in San Diego, California. He has made significant contributions to the field of immunology, particularly in the treatment of allergic conditions. With a total of two patents to his name, Nycholat's work focuses on innovative methods to modulate immune responses.
Latest Patents
Nycholat's latest patents include groundbreaking research on desensitizing mast cells. His first patent describes compositions and methods that are useful for treating and inhibiting allergic conditions. This includes reducing the incidence of mast cell-mediated anaphylaxis in subjects. The compositions feature a carrier that displays an antigen alongside a Siglec ligand that binds to a Siglec on a mast cell.
His second patent involves liposome targeting compounds designed for targeting cells that express sialic acid-binding Ig-like lectin (Siglec). These liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. They also incorporate or encapsulate a biological agent, such as an antigen or therapeutic agent, which can be delivered to the target cell to modulate or kill it. This invention provides methods for targeted delivery of antigens and for modulating immune cells or immune responses.
Career Highlights
Corwin Nycholat is affiliated with The Scripps Research Institute, where he continues to advance his research in immunology. His work has garnered attention for its potential to improve treatment options for individuals suffering from severe allergic reactions.
Collaborations
Nycholat collaborates with esteemed colleagues, including James C. Paulson and Weihsu Chen. Their combined expertise enhances the research and development of innovative solutions in the field of immunology.
Conclusion
Corwin Nycholat's contributions to the field of allergy treatment and immune modulation are noteworthy. His innovative patents reflect a commitment to advancing medical science and improving patient outcomes. Through his work at The Scripps Research Institute, he continues to make strides in understanding and treating allergic conditions.